前言
一年一度的肿瘤领域盛会——2024年欧洲肿瘤内科学会亚洲年会（ESMO ASIA）将于12月6日至8日在新加坡隆重举行，届时将揭示众多国际重要的临床科研成果。本文将聚焦于肝胆胰肿瘤的最新研究进展，探讨那些有潜力改变临床实践的关键研究。让我们一起期待这些前沿成果的发布，推动肝胆胰领域的持续创新与发展！
Proffered paper session
摘要号：126O
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis
纳武利尤单抗（NIVO）联合伊匹木单抗（IPI）对比仑伐替尼（LEN）或索拉非尼（SOR）作为不可切除肝细胞癌（uHCC）的一线（1L）治疗：CheckMate 9DW亚洲亚组分析
讲者：Thomas Yau 香港大学
Mini Oral session
摘要号：132MO
Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): updated results from a phase 1 study
抗claudin18.2 (CLDN18.2) 抗体药物偶联物 (ADC) IBI343 在晚期胰腺导管腺癌 (PDAC) 患者中的应用：1期研究的更新结果
讲者：虞先濬 复旦大学附属肿瘤医院
Poster Display session
摘要号：136P
Tislelizumab combined with donafenib and GEMOX as first-line treatment for advanced biliary tract cancer: a single-center, single-arm, phase 2 study Tislelizumab 联合多纳非尼和 GEMOX
作为晚期胆道癌一线治疗：一项单中心、单组、II 期临床研究
讲者：赵一鸣 复旦大学附属肿瘤医院
摘要号：137P
A single-arm, multicenter, phase II study of hepatic arterial infusion chemotherapy (HAIC) combined with donafenib and sintilimab as first-line treatment for unresectable intrahepatic cholangiocarcinoma (CHANCE 2203)
肝动脉灌注化疗（HAIC）联合多纳非尼和信迪利单抗作为不可切除的肝内胆管癌一线治疗的单组、多中心、II 期研究（CHANCE 2203）
讲者：滕皋军 东南大学附属中大医院
摘要号：140P
Tinengotinib (TT-00420) in Combination with Atezolizumab (atezo) in Chinese Patients (pts) with Biliary Tract Carcinoma (BTC): Efficacy and Safety Results from a Phase Ib/II Study
Tinengotinib (TT-00420) 联合阿替利珠单抗 (atezo) 用于中国胆道癌 (BTC) 患者的有效性和安全性：Ib/II 期研究结果
讲者：张攀攀 北京大学肿瘤医院
摘要号：142P
Lenvatinib Demonstrates Enhanced Efficacy in IDH1-Mutated Cholangiocarcinoma with Hypervascular Features on Abdominal CT
仑伐替尼在腹部 CT 显示富血管特征的 IDH1 突变胆管癌中具有增强疗效
讲者：Wen-Chi Wu 台北荣民总医院
摘要号：143P
Claudin-18.2 Is a Poor Prognostic Indicator for Intrahepatic Cholangiocarcinoma
Claudin-18.2 是肝内胆管癌的不良预后指标
讲者：Yu Hsuan Kuo 台湾中山大学
摘要号：145P
Efficacy and Safety in the KEYNOTE-966 Study of Pembrolizumab (pembro) + Gemcitabine and Cisplatin (gem/cis) for Advanced Biliary Tract Cancer (BTC): Impact of Hepatitis B Virus (HBV) Infection
KEYNOTE-966研究中帕博利珠单抗 (pembro) 联合吉西他滨和顺铂 (gem/cis) 用于晚期胆道癌 (BTC) 的疗效和安全性：乙型肝炎病毒 (HBV) 感染的影响
讲者：Thomas Yau 香港大学
摘要号：146P
A retrospective study of the efficacy of gemcitabine combined with capecitabine versus capecitabine alone for biliary tract cancer after curative resection
吉西他滨联合卡培他滨与卡培他滨单药治疗胆道癌根治性切除术后疗效的回顾性研究
讲者：Jiaman Ma 四川大学华西医院
摘要号：150P
The Prognostic Nutritional Index is linked to textbook outcomes and the status of lymphocyte infiltration in patients with perihilar cholangiocarcinoma
预后营养指数与肝门胆管癌患者的教科书结果和淋巴细胞浸润状态相关
讲者：Qin-qin Liu 中山大学
摘要号：152P
Spatial analyses revealed CXCL5 and SLC6A14 as the markers of microvascular invasion in intrahepatic cholangiocarcinoma
空间分析显示CXCL5和SLC6A14是肝内胆管癌微血管侵袭的标志物
讲者：Guangyu Fan 中国医学科学院北京协和医学院
摘要号：153P
Preliminary activity of Camrelizumab plus gemcitabine and oxaliplatin in the transformation of unresectable gallbladder cancer：a single arm, phase II, prospective clinical study
卡瑞利珠单抗联合吉西他滨和奥沙利铂对不可切除胆囊癌转化的初步活性：一项单组、II 期、前瞻性临床研究
讲者：Rui Zhang 中山大学孙逸仙纪念医院
摘要号：174P
Improved Tumour Penetration and Efficacy of anti-GPC3 CAR-T Cells in Hepatocellular Carcinoma via Locoregional Delivery
通过局部给药提高抗GPC3 CAR-T细胞在肝细胞癌中的肿瘤渗透性和疗效
讲者：Peter WANG 香港中文大学
摘要号：197P
Efficacy and safety of lenvatinib plus adebrelimab combined with hepatic arterial infusion chemotherapy (HAIC) for unresectable biliary tract cancer
仑伐替尼联合阿得贝利单抗与肝动脉灌注化疗（HAIC）治疗不可切除胆道癌的疗效和安全性
讲者：Hongjie Cai 中山大学附属第一医院
摘要号：201P
Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: updated efficacy and safety results from the phase 2 NeoLEAP-HCC study
围手术期使用派姆单抗和仑伐替尼治疗可切除肝细胞癌：2期NeoLEAP-HCC研究的最新疗效和安全性结果
讲者：Kui Wang 海军军医大学附属第三医院
摘要号：202P
Hepatic Arterial Infusion Tislelizumab and Chemotherapy plus DEB-TACE in Combination with Lenvatinib for First-line Treatment of unresectable HCC: A Prospective, Single arm, Phase 2 Study (HAITC Study)
肝动脉灌注替雷利珠单抗联合化疗及DEB-TACE与仑伐替尼一线治疗不可切除的肝细胞癌：一项前瞻性、单臂、II期研究（HAITC研究）
讲者：HAIPENG Yu 天津医科大学肿瘤医院
摘要号：204P
Concurrent Transarterial Chemoembolization plus Atezolizumab and Bevacizumab in Unresectable Hepatocellular carcinoma: Interim Analysis from a Multicenter Real-world Study (CHANCE 023)
同期经动脉化疗栓塞联合阿替利珠单抗和贝伐珠单抗治疗不可切除肝细胞癌：多中心真实世界研究（CHANCE 023）的中期分析
讲者：Rong Yan 东南大学附属中大医院
摘要号：205P
Transarterial Chemoembolization with Immune Checkpoint Inhibitors and Anti-VEGF Antibody/Tyrosine Kinase Inhibitors as First-Line Treatment for Intermediate-Stage Hepatocellular Carcinoma (CHANCE2202): A Target Trial Emulation Study
经动脉化疗栓塞联合免疫检查点抑制剂和抗VEGF抗体/酪氨酸激酶抑制剂作为中晚期肝细胞癌的一线治疗（CHANCE2202）：一项靶向试验模拟研究
讲者：Jian-Jian Chen 东南大学附属中大医院
摘要号：206P
Avatrombopag for the treatment of immune checkpoint inhibitor/targeted therapy‑related thrombocytopenia in patients with hepatocellular carcinoma: A prospective, multicenter, single-arm trial
阿伐曲泊帕用于治疗肝细胞癌患者免疫检查点抑制剂/靶向治疗相关血小板减少症：一项前瞻性、多中心、单臂试验
讲者：Yong-Shuai Wang 中国科学技术大学附属第一医院
摘要号：207P
FOLFOX-HAIC combined with sintilimab and bevacizumab for advanced hepatocellular carcinoma: a single-arm, phase II study
FOLFOX-HAIC联合信迪利单抗和贝伐单抗治疗晚期肝细胞癌：一项单组 II 期研究
讲者：Zizhuo Wang 华中科技大学同济医学院附属同济医院
摘要号：209P
Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma: a phase 2 trial
肝动脉灌注化疗序贯动脉栓塞联合仑伐替尼和替雷利珠单抗治疗高危不可切除性肝细胞癌患者：一项2期临床试验
讲者：Jian-Hong Zhong 广西医科大学肿瘤医院
摘要号：211P
Multi-center, retrospective GUIDANCE001 trial comparing TACE with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: survival benefit in intermediate or advanced, but not early, stages
多中心、回顾性GUIDANCE001试验比较经导管动脉化疗栓塞（TACE）联合或不联合酪氨酸激酶抑制剂和免疫检查点抑制剂作为转化治疗用于治疗不可切除的肝细胞癌：在中晚期而非早期阶段有生存获益。
讲者：DaLong Yang 广西医科大学肿瘤医院
摘要号：212P
FOLFOX-Based Hepatic Arterial Infusion Chemotherapy Combined with Sequential Drug-Eluting Bead Transarterial Chemoembolization for unresectable Large Hepatocellular Carcinoma
基于FOLFOX的肝动脉灌注化疗联合序贯药物洗脱珠子经导管动脉化疗栓塞治疗不可切除的大肝细胞癌
讲者：Rongce Zhao 中山大学肿瘤防治中心
摘要号：213P
Duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors: a prospective, multicentric cohort study
辅助免疫检查点抑制剂在具有高危复发因素的肝细胞癌中的应用时长：一项前瞻性、多中心队列研究
讲者：Jia-Yong Su 广西医科大学肿瘤医院
摘要号：214P
Updated results from phase II study of HAIC plus sintilimab and bevacizumab biosimilar in patients with advanced hepatocellular carcinoma (HCC)
更新了在晚期肝细胞癌（HCC）患者中使用HAIC联合信迪利单抗和贝伐珠单抗生物类似物的II期研究结果
讲者：Haibin Zhang 上海东方肝胆外科医院
摘要号：215P
Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with portal vein tumor thrombosis (PVTT) treated with Camrelizumab, Apatinib plus FOLFOX Chemotherapy
探索性评估卡瑞利珠单抗联合阿帕替尼及FOLFOX化疗治疗伴有门静脉肿瘤血栓的肝细胞癌患者的疗效和安全性结果
讲者：Linhui Peng 中山大学孙逸仙纪念医院
摘要号：217P
The efficacy and safety of tislelizumab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after radical reaction
替雷利珠单抗用于根治性术后高复发风险肝细胞癌辅助治疗的疗效和安全性
讲者：Ning Peng 广西医科大学附属第一医院
摘要号：221P
Survival Analysis of TACE Monotherapy vs. Combination Therapy in BCLC B and C Stage Hepatocellular Carcinoma: A Retrospective Cohort Study
BCLC B期和C期肝细胞癌中TACE单药治疗与联合治疗的生存分析：一项回顾性队列研究
讲者：Chengxiang Guo 浙江大学医学院附属第一医院
摘要号：222P
The activity and safety of icaritin for patients with unresectable hepatocellular carcinoma：A real world, retrospective study
淫羊藿素对不可切除肝细胞癌患者的活性和安全性：一项真实世界回顾性研究
讲者：Zeng Hui 浙江省肿瘤医院
摘要号：223P
Hepatic artery infusion chemotherapy (HAIC) combined with camrelizumab and apatinib as conversion therapy for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial
肝动脉灌注化疗 (HAIC) 联合卡瑞利珠单抗和阿帕替尼作为初始不可切除的肝细胞癌 (HCC) 的转化疗法：一项前瞻性、单臂 II 期试验。
讲者：Xu Zhou 山东省立医院
摘要号：224P
Neoadjuvant therapy versus initial hepatectomy for resectable intermediate or advanced hepatocellular carcinoma (GUIDANCE002): a multicenter, retrospective cohort study
可切除中晚期肝细胞癌的新辅助治疗与初始肝切除术 (GUIDANCE002)：一项多中心、回顾性队列研究
讲者：Jian-Hong Zhong 广西医科大学附属肿瘤医院
摘要号：225P
Real adjuvant transarterial chemoembolization is not associated with good survival in most patients with hepatocellular carcinoma: a multicenter retrospective study
真正的辅助经动脉化疗栓塞术与大多数肝细胞癌患者的良好生存无关：一项多中心回顾性研究
讲者：Jian-Rong Li 广西医科大学附属肿瘤医院
摘要号：226P
Immune checkpoint inhibitor rechallenge in advanced hepatocellular carcinoma: a retrospective cohort study
晚期肝细胞癌中免疫检查点抑制剂的再次治疗：一项回顾性队列研究
讲者：Jing-Kun Chen 广西医科大学附属肿瘤医院
摘要号：227P
Adjuvant tislelizumab plus TACE in resected high-risk hepatocellular carcinoma (ATTACK): preliminary analysisof a prospective cohort study
替雷利珠单抗联合 TACE 治疗切除的高危肝细胞癌（ATTACK）：一项前瞻性队列研究的初步分析
讲者：Jiao Liu 上海公共卫生临床中心
摘要号：228P
Arsenic sulfide enhances the therapeutic effect of hepatocellular carcinoma immunotherapy through STAT3-THBS1/CD47 pathway
硫化砷通过STAT3-THBS1/CD47通路增强肝细胞癌免疫治疗的治疗效果
讲者：Ting Kang 上海交通大学医学院附属新华医院
摘要号：229P
The Efficacy and Safety of Avatrombopag in the treatment of Thrombocytopenia Secondary to Targeted and Immunotherapy in Hepatocellular Carcinoma Avatrombopag
阿伐曲泊帕在治疗肝细胞癌靶向和免疫治疗引起的血小板减少症中的有效性和安全性
讲者：Xuehui Peng 陆军军医大学附属第二医院
摘要号：230P
Individual-specific Edge-network of Gene Interactions Identified a Robust Prognostic Score in Hepatocellular Carcinoma Patients
个体特异性基因相互作用边缘网络确定了肝细胞癌患者的可靠预后评分
讲者：Ke Xu 安徽医科大学
摘要号：231P
CT Image-Based Artificial Intelligence Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Immunotherapy Combined with Anti-Angiogenic Drugs in Hepatocellular Carcinoma
基于CT图像的人工智能量化肿瘤内异质性以预测肝细胞癌免疫治疗联合抗血管生成药物的治疗反应
讲者：Zhi-Cheng Jin 东南大学附属中大医院
摘要号：232P
Selective internal radiation therapy with Yttrium-90 (Y-90) resin microspheres for unresectable hepatocellular carcinoma: Experience of a single center in China
钇-90（Y-90）树脂微球选择性内放射治疗不可切除的肝细胞癌：中国单中心经验
讲者：Xiaobin Feng 清华大学附属北京清华长庚医院
摘要号：233P
Association of circulating inflammatory marker ISG15 with clinical factors and survival in patients with liver cancer
循环炎症标志物ISG15与肝癌患者临床因素和生存期的关系
讲者：Winnie Yeo 香港中文大学
摘要号：236P
Characteristics and Prognosis of Primary and Acquired Resistance to Immune Checkpoint Inhibitors Combination Treatment in Unresectable Hepatocellular Carcinoma
不可切除的肝细胞癌中原发性和获得性免疫检查点抑制剂联合治疗耐药的特征和预后
讲者：Xiangqi Chen 中国医学科学院北京协和医院
摘要号：237P
Radiotherapy with or without Immune checkpoint inhibitors and tyrosine kinase inhibitors in Hepatocellular Carcinoma with severe macrovascular invasion: a retrospective cohort study
放射治疗联合或不联合免疫检查点抑制剂和酪氨酸激酶抑制剂在严重大血管侵犯的肝细胞癌中的应用：一项回顾性队列研究
讲者：Qian-qian Tang 广西医科大学附属肿瘤医院
摘要号：239P
Adjuvant TACE Combined with Tislelizumab in Patients with Resected Hepatocellular Carcinoma at High Risk of Recurrence: An Open-label, Multicenter, Phase 2 Trial
辅助性TACE联合替雷利珠单抗治疗切除后高复发风险的肝细胞癌患者：一项开放标签、多中心、2期试验
讲者：Tao Ma 浙江大学医学院附属第一医院
摘要号：240P
Efficacy and Safety in the KEYNOTE-966 Study of Pembrolizumab (pembro) + Gemcitabine and Cisplatin (gem/cis) for Advanced Biliary Tract Cancer (BTC): Impact of Hepatitis B Virus (HBV) Infection
KEYNOTE-966研究中帕博利珠单抗 (pembro) 联合吉西他滨和顺铂 (gem/cis) 用于晚期胆道癌 (BTC) 的疗效和安全性：乙型肝炎病毒 (HBV) 感染的影响
讲者：Thomas Yau 香港大学
摘要号：242P
Selective internal radiation therapy with Yttrium-90 (Y-90) resin microspheres for unresectable hepatocellular carcinoma: Experience of a single center in China
钇-90（Y-90）树脂微球选择性内放射治疗不可切除的肝细胞癌：中国单中心经验
讲者：XiaoLei Xu 清华大学附属北京清华长庚医院
摘要号：249P
The intratumoral metabolic characterization and potential mechanisms in pancreatic ductal adenocarcinoma
肿瘤内代谢特征及胰腺导管腺癌的潜在机制
讲者：Dong Luo 中南大学湘雅医院
摘要号：252P
Safety and Efficacy of XELOXIRI Regimen in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
XELOXIRI方案在不可切除的胰腺导管腺癌患者中的安全性和有效性
讲者：Biyang Cao 中国医学科学院北京协和医院
摘要号：257P
“H” to “H” precision neoadjuvant chemotherapy can improve the resectable rate in pancreatic cancer
“H”到“H”精准新辅助化疗可提高胰腺癌切除率
讲者：Yonggang He 陆军军医大学附属第二医院
摘要号：259P
Irinotecan liposome-based regimen in Chinese patients with advanced pancreatic cancer: a prospective, multi-center, observational real-world study
伊立替康脂质体治疗中国晚期胰腺癌患者：一项前瞻性、多中心、观察性真实世界研究
讲者：Jin Xu 复旦大学附属肿瘤医院
摘要号：260P
NALIRIFOX as subsequent therapy for metastatic pancreatic cancer after Gemcitabine-based chemotherapy: a real-world experience in single center
NALIRIFOX 作为吉西他滨化疗后转移性胰腺癌的后续治疗：单中心真实世界经验
讲者：Hisn-Chen Lin 台中荣民总医院
编辑：Aurora
排版：Aurora
执行：Babel
